Genomed Spólka Akcyjna (WSE:GEN)

Poland flag Poland · Delayed Price · Currency is PLN
26.80
0.00 (0.00%)
At close: Apr 27, 2026
12.61%
Market Cap 34.35M
Revenue (ttm) 29.12M
Net Income (ttm) 3.36M
Shares Out 1.32M
EPS (ttm) 2.54
PE Ratio 10.23
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 108
Average Volume 100
Open 26.80
Previous Close 26.80
Day's Range 26.80 - 26.80
52-Week Range 15.40 - 33.00
Beta 0.11
RSI 51.43
Earnings Date May 14, 2026

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2007
Employees 56
Stock Exchange Warsaw Stock Exchange
Ticker Symbol GEN
Full Company Profile

Financial Performance

In 2025, Genomed Spólka Akcyjna's revenue was 29.12 million, an increase of 26.58% compared to the previous year's 23.01 million. Earnings were 3.36 million, an increase of 203.87%.

Financial Statements

News

There is no news available yet.